Participants sought for Market Research on Advanced PCa

[Paul Edwards]

[The survey has been completed.  Participants are no longer required. 15/12/2015]

 

We have received the following email from the Prostate Cancer Foundation Australia:

 

"A Sydney based organisation are conducting market research on behalf of a pharmaceutical company to better understand the perspectives & needs of people living with and being treated for Advanced Prostate Cancer.  The outcome of this study will look to guide support and education initiatives for these patients.

 

Whilst this research is being conducted separately from Prostate Cancer Foundation Australia, the research team here at PCFA have reviewed and approved the study as an acceptable opportunity to participate for those interested (though you are under no obligation). If you or someone you know might like to participate please refer them to the key points below including: how you will participate, who to contact and benefits you may receive for the time given.

 

Key points:

1. The study consists of a 1-hour interview and short homework task to be completed before the interview.
2. The interview can be conducted at the time and location convenient to you.
3. This is an ‘opt-in’ study – if you do not wish to participate please ignore this notice.
4. This is a confidential and anonymous study.  If you choose to participate, your details will NOT be shared with the researchers client.
5. Each person who participates in the study will receive $120 for their time. Alternatively, participants can choose to transfer this reimbursement as a donation, to a charity of their choice.
6. There is a quota in place for this study, which means places are limited.
7. Please contact – Jennifer Kensey if you have any further questions or are interested in participating in this study on 0403 902 454 or jenniferkensey@optusnet.com.au"

 

Although not stated in the email from PCFA, the market research organisation is seeking to interview prostate cancer patients who are being treated with Zytiga (abiraterone) or Xtandi (enzalutamide).